Sinead M.
- Country
- Ireland
- Department
- Neurology
Research Overview
- Phase 3 Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
- Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acoramidis Hydrochloride for Transthyretin Amyloidosis Prevention in Asymptomatic TTR Variant Carriers
- A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE)
Data & Insights
Has run more than one trial at 30 of 47 partner sites.
Specializations
Urologic Oncology
Sinead Murphy is involved in clinical research across prostate cancer, urothelial carcinoma, and bladder cancer, with attention to both localized and advanced disease settings. The portfolio also includes treatment strategies for metastatic and castration-resistant disease.
- Metastatic castration-resistant prostate cancer
- Muscle-invasive bladder cancer
- Advanced urothelial cancer
- Localized very high-risk prostate cancer
Her work extends to androgen deprivation therapy-based combinations, immune checkpoint inhibition, and bladder-directed approaches in aggressive genitourinary malignancies.
Thoracic and Gastrointestinal Malignancies
Her trial activity includes non-small cell lung cancer, advanced lung cancer, gastric cancer, gastroesophageal junction adenocarcinoma, and colorectal cancer. These studies reflect interest in both first-line and later-line treatment options for solid tumors with high unmet need.
- Non-small cell lung cancer
- Advanced colorectal cancer with KRAS G12C mutation
- Gastric and GEJ adenocarcinoma
- Pan-tumor solid malignancies
The therapeutic focus includes PD-1/PD-L1-based immunotherapy, targeted treatment combinations, and biomarker-defined disease subsets.
Renal and Melanoma Therapeutics
Her research landscape includes renal cell carcinoma, clear cell renal cell carcinoma, and melanoma, with interest in advanced and metastatic presentations. These studies address both systemic disease control and adjuvant treatment settings.
- Advanced renal cell carcinoma
- Metastatic clear cell renal cell carcinoma
- Resectable melanoma
- Adjuvant renal cancer therapy
Her involvement spans checkpoint inhibitor combinations and emerging targeted approaches in kidney cancer and melanoma.
Neurology and Cognitive Disorders
Within neurology, Sinead Murphy is engaged in studies of Alzheimer’s disease, mild cognitive impairment, dementia-related agitation, stroke, and multiple sclerosis. Her portfolio also includes acute neurological and cerebrovascular conditions.
- Alzheimer’s disease and mild cognitive impairment
- Agitation in dementia
- Secondary progressive multiple sclerosis
- Stroke
Her therapeutic interests cover cognitive decline, behavioral symptoms of dementia, and neuroinflammatory disease.
Critical Care, Respiratory Disease, and Inflammation
Her clinical trial activity also reaches critically ill patients, COVID-19, acute respiratory tract infection, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. This area includes both inpatient supportive care and chronic respiratory disease management.
- Critical illness and trauma
- COVID-19 and acute respiratory infection
- Chronic obstructive pulmonary disease
- Progressive pulmonary fibrosis
Her research interest includes respiratory failure, anti-inflammatory therapy, and supportive interventions in severe systemic illness.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.